Key result
Zofenopril cuts 6-week death or severe CHF by ~34% vs placebo in AMI.
Why the study?
Does zofenopril provide cardioprotective effects beyond blood pressure control compared to other ACE inhibitors?
Does zofenopril provide cardioprotective effects beyond blood pressure control compared to other ACE inhibitors?
Effect estimate: RRR 34% (95% CI 8-54%)
p-value: p=0.018
Zofenopril may offer unique cardioprotective benefits beyond standard blood pressure control compared to other ACE inhibitors.
May support zofenopril in acute MI; leaves open whether benefits exceed other ACE inhibitors.
S system, resulting in a cardioprotective effect. The efficacy and safety of zofenopril have been extensively evaluated and proved in the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) program in numerous clinical settings. The pharmacological features and ancillary characteristics of zofenopril with potent cardioprotective effects seem to differentiate it from other ACEIs and to confer further benefits to patients.
No takes yet. Share an insight, caveat, or question.
Borghi et al. (2020) conducted a review in Acute myocardial infarction (n=3,630). Zofenopril vs. Placebo, lisinopril, or ramipril was evaluated on Death or severe congestive heart failure at 6 weeks (SMILE-1 trial) (RRR 34%, 95% CI 8-54%, p=0.018).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: